Equillium Banner Image

Equillium has reached its limit for free report views

Work for Equillium? Upgrade Your Profile and unlock all your annual reports.


  • Ticker EQ
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Equillium Logo Image
  • 11-50 Employees
  • Based in San Diego, California
Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products for autoimmune and inflammatory disorders, or immuno-inflammation, with high unmet medical need. Their initial product candidate, EQ001, is a first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cellMore activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis. They believe EQ001 may have broad therapeutic utility and their current pipeline is focused on developing EQ001 as a best-in-class treatment for multiple severe immuno-inflammatory disorders.

Most Recent Annual Report

MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Equillium has reached its limit for free report views.

Older/Archived Annual Reports